SciELO - Scientific Electronic Library Online

SciELO - Scientific Electronic Library Online

Article References

KIMMEL, April D; LOSINA, Elena; FREEDBERG, Kenneth A  and  GOLDIE, Sue J. Diagnostic tests in HIV management: a review of clinical and laboratory strategies to monitor HIV-infected individuals in developing countries. Bull World Health Organ [online]. 2006, vol.84, n.7, pp.581-588. ISSN 0042-9686.

    1. Mellors JW, Munoz A, Giorgi JV, Margolick JB, Tassoni CJ, Gupta P, et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997;126:946-54. [ Links ]

    2. Hughes MD, Johnson VA, Hirsch MS, Bremer JW, Elbeik T, Erice A, et al. Monitoring plasma HIV-1 RNA levels in addition to CD4+ lymphocyte count improves assessment of antiretroviral therapeutic response. ACTG 241 Protocol Virology Substudy Team. Ann Intern Med 1997;126:929-38. [ Links ]

    3. Masur H, Ognibene FP, Yarchoan R, Shelhamer JH, Baird BF, Travis W, et al. CD4 counts as predictors of opportunistic pneumonias in human immunodeficiency virus (HIV) infection. Ann Intern Med 1989;111:223-31. [ Links ]

    4. World Health Organization. Safe and effective use of antiretrovirals. Guidance module 4. Guidance modules on antiretroviral treatments. WHO/ASD/98.1; UNAIDS/98.7. 1998. Available from: [ Links ]

    5. World Health Organization/UNAIDS. Laboratory requirements for the safe and effective use of antiretrovirals. Guidance module 5. Guidance modules on antiretroviral treatments. WHO/ASD/98.1; UNAIDS/98.7. 1998. Available from: [ Links ]

    6. World Health Organization. Scaling up antiretroviral therapy in resource-limited settings: treatment guidelines for a public health approach. 2003 Revision. Geneva: WHO; 2003. Available from: [ Links ]

    7. World Health Organization. Treating 3 million by 2005: Making it happen. The WHO strategy: the WHO and UNAIDS global initiative to provide antiretroviral therapy to 3 million people with HIV/AIDS in developing countries by the end of 2005. Geneva: WHO; 2003. Available from: [ Links ]

    8. World Bank. World Bank List of Economies. The World Bank; 2004. Available from: [ Links ]

    9. Centers for Disease Control and Prevention. Destinations. National Center for Infectious Diseases: Travelers' Health. CDC; 2003. Available from: [ Links ]

    10. Sox HC. The evaluation of diagnostic tests: principles, problems, and new developments. Annu Rev Med 1996;47:463-71. [ Links ]

    11. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM, et al. Towards complete and accurate reporting of studies of diagnostic accuracy: The STARD Initiative. Ann Intern Med 2003;138:40-4. [ Links ]

    12. Lyamuya EF, Kagoma C, Mbena EC, Urassa WK, Pallangyo K, Mhalu FS, et al. Evaluation of the FACScount, TRAx CD4 and Dynabeads methods for CD4 lymphocyte determination. J Immunol Methods 1996;195:103-12. [ Links ]

    13. Respess R, Cachafeiro A, Fiscus S, Newman D, Branson B, Varnier O, et al. Evaluation of a commercially available ultrasensitive p24 antigen viral load assay in samples from patients infected with genetically diverse HIV-1 from different geographic settings [Abstract 669]. 10th Conference on Retroviruses and Opportunistic Infections, Boston, MA, 10–14 February 2003. Available from: [ Links ]

    14. Bonard D, Rouet F, Toni TA, Minga A, Huet C, Ekouevi DK, et al. Field evaluation of an improved assay using a heat-dissociated p24 antigen for adults mainly infected with HIV-1 CRF02_AG strains in Côte d'Ivoire, West Africa. J Acquir Immune Defic Syndr 2003;34:267-73. [ Links ]

    15. Karcher H, Downing R, Ali M, Kagwire F, Weide A, Harms G. Comparison of a manual CD4+ T cell counting method with a standard dual-platform flow cytometry protocol in a Ugandan rural HIV treatment cohort [Abstract LB46]. The 2nd IAS Conference on HIV Pathogenesis and Treatment, Paris, France,13–16 July 2003. Available from: = 11100 [ Links ]

    16. Stevens G, Rekhviashvili N, Scott L, Stevens W. Affordable HIV-1 monitoring: a direct comparison of an improved p24 antigen assay and the Roche Amplicor Monitor assay [Abstract 475]. The 2nd IAS Conference on HIV Pathogenesis and Treatment, Paris, France, 13–16 July 2003. Available from: = 9880 [ Links ]

    17. Ghate MV, Mehendale SM, Mahajan BA, Yadav R, Brahme RG, Divekar AD, et al. Relationship between clinical conditions and CD4 counts in HIV-infected persons in Pune, Maharashtra, India. Natl Med J India 2000;13:183-7. [ Links ]

    18. Schechter M, Zajdenverg R, Machado LL, Pinto ME, Lima LA, Perez MA. Predicting CD4 counts in HIV-infected Brazilian individuals: a model based on the World Health Organization staging system. J Acquir Immune Defic Syndr 1994;7:163-8. [ Links ]

    19. Hofer CB, Pinto ME, Zajdenverg R, Schechter M. p24 antigenaemia in HIV-1 infected Brazilians correlates with other markers of disease progression. J Infect 1994;29:129-31. [ Links ]

    20. Sehgal S, Datta U, Mujtaba S, Sood A, Vinayak VK. Cellular and serological markers of disease activity in Indian patients with HIV/AIDS. Methods Cell Sci 2002;24:107-14. [ Links ]

    21. Mwaba P, Cassol S, Pilon R, Chintu C, Janes M, Nunn A, et al. Use of dried whole blood spots to measure CD4+ lymphocyte counts in HIV-1-infected patients. Lancet 2003;362:1459-60. [ Links ]

    22. Graham S, Rodriguez W, Christodoulides N, Romanovicz D, Dixon M, Goodey A, et al. Field testing of a portable microchip assay for CD4 counts in Bostwana [Abstract 687]. The 2nd IAS Conference on HIV Pathogenesis and Treatment, Paris, France, 13–16 July 2003. Available from: = 10372 [ Links ]

    23. Diagbouga S, Durand G, Sanou PT, Dahourou H, Ledru E. Evaluation of a quantitative determination of CD4 and CD8 molecules as an alternative to CD4+ and CD8+ T lymphocyte counts in Africans. Trop Med Int Health 1999;4:79-84. [ Links ]

    24. Kannangai R, Ramalingam S, Jesudason MV, Vijayakumar TS, Abraham OC, Zachariah A, et al. Correlation of CD4(+) T-Cell counts estimated by an immunocapture technique (Capcellia) with viral loads in human immunodeficiency virus-seropositive individuals. Clin Diagn Lab Immunol 2001;8:1286-8. [ Links ]

    25. Wilja M, Janossy G, Glencross D, Barnett D, Mermin J, Downing RG. Less expensive CD4+ T cell monitoring using panleucogating [Abstract MoPeB3105]. The XIV International AIDS Conference, Barcelona, Spain, 7–12 July 2002. Available from: = 5137 [ Links ]

    26. Kohreanudom S. The benefit of using total lymphocyte count for monitoring the treatment of HIV/AIDS patients in Thailand [Abstract MoPeB3103]. XIV International AIDS Conference, Barcelona, Spain, 7–12 July 2002. Available from: = 3646 [ Links ]

    27. Kumarasamy N, Mahajan AP, Flanigan TP, Hemalatha R, Mayer KH, Carpenter CC, et al. Total lymphocyte count (TLC) is a useful tool for the timing of opportunistic infection prophylaxis in India and other resource-constrained countries. J Acquir Immune Defic Syndr 2002;31:378-83. [ Links ]

    28. Mane A, Patel A, Pujari S, Gupte N, Patel J, Patel K, et al. Total lymphocyte counts (TLC) is a poor surrogate for CD4 counts amongst asymptomatic HIV infected patients in resource limited settings [Abstract 481]. The 2nd IAS Conference on HIV Pathogenesis and Treatment, Paris, France, 13–16 July 2003. Available from: = 10643 [ Links ]

    29. van der Ryst E, Kotze M, Joubert G, Steyn M, Pieters H, van der Westhuizen M, et al. Correlation among total lymphocyte count, absolute CD4+ count, and CD4+ percentage in a group of HIV-1-infected South African patients. J Acquir Immune Defic Syndr Hum Retrovirol 1998;19:238-44. [ Links ]

    30. Kumarasamy N, Chaguturu SK, Balakrishnan P, Mayer KH, Solomon S, Flanigan TP. Low-cost strategies to monitor highly active antiretroviral therapy in resource-limited settings [Abstract 589]. 11th Conference on Retroviruses and Opportunistic Infections, San Francisco (CA), 8–11 February 2004. Available from: [ Links ]

    31. Hodara V, Monticelli A, Pampuro S, Salomón H, Jauregui Rueda H, Libonatti O. HIV-1 viral load: comparative evaluation of three commercially available assays in Argentina. Acta Physiol Pharmacol Ther Latinoam 1998;48:107-13. [ Links ]

    32. Toure-Kane C, Diop-Ndiaye H, Diop A, Diaw PA, Gautron JL, Esnault A, et al. Evaluation of LCx HIV RNA Quantitative assay performance on non-B patients treated by HAART: comparison with bDNA in Senegal [Abstract 680]. The 2nd IAS Conference on HIV Pathogenesis and Treatment, Paris, France, 13–16 July 2003. Available from: = 10662 [ Links ]

    33. Ramalingam S, Kannangai R, Zachariah A, Mathai D, Abraham C. CD4 counts of normal and HIV-infected south Indian adults: do we need a new staging system? Natl Med J India 2001;14:335-9. [ Links ]

    34. Ruxrungtham K, Ubolyam S, Hassink EA, Ungsedhapand C, Kroon E, Duncombe C, et al. Significant differences between plasma HIV-1 RNA assays in HIV-1 subtype E infected patients treated with antiretroviral therapy. Asian Pac J Allergy Immunol 2002;20:105-11. [ Links ]

    35. Nkengasong JN, Bile C, Kalou M, Maurice C, Boateng E, Sassan-Morokro M, et al. Quantification of RNA in HIV type 1 subtypes D and G by NucliSens and Amplicor assays in Abidjan, Ivory Coast. AIDS Res Hum Retroviruses 1999;15:495-8. [ Links ]

    36. World Health Organization, United Nations Children's Fund, Joint United Nations Programme on HIV/AIDS (UNAIDS), Médecins Sans Frontières. Sources and prices of selected medicines and diagnostics for people living with HIV/AIDS. A joint UNICEF, UNAIDS, WHO, MSF project. 2005. 6th edition. Available from: [ Links ]

    37. Kent DM, McGrath D, Ioannidis JP, Bennish ML. Suitable monitoring approaches to antiretroviral therapy in resource-poor settings: setting the research agenda. Clin Infect Dis 2003;37:S13-24. [ Links ]

    38. Mukherjee JS, Farmer PE, Niyizonkiza D, McCorkle L, Vanderwarker C, Teixeira P, et al. Tackling HIV in resource poor countries. BM J 2003;327:1104-6. [ Links ]

    39. Rabkin M, El-Sadr W, Katzenstein DA, Mukherjee J, Masur H, Mugyenyi P, et al. Antiretroviral treatment in resource-poor settings: clinical research priorities. Lancet 2002;360:1503-5. [ Links ]

    40. Vermund SH, Powderly WG, on behalf of the Infectious Diseases Society of America (IDSA) and the HIV Medicine Association of IDSA. Developing a human immunodeficiency virus/acquired immunodeficiency syndrome therapeutic research agenda for resource-limited countries: a consensus statement. Clin Infect Dis 2003;37:S4-12. [ Links ]